Here’s what you need to know:
1. At present, only one patient has been treated using this therapy; however, the researchers estimate that tens of thousands of patients could be eligible for this treatment each year.
2. The therapy uses a patient’s own immune cells for a personalized treatment.
3. The therapy targets a genetic mutation known as KRAS G12D, which is related to gastrointestinal cancers.
4. This mutated gene causes roughly 90 percent of often lethal pancreatic cancers and 45 percent of colorectal cancers.
5. Eventually, the researchers believe this type of immunotherapy may be applicable to many cancer types.
More articles on gastroenterology and endoscopy:
Biggest hepatology breakthroughs in 2016: Nonalcoholic steatohepatitis, primary biliary cholangitis
Dr. Gary Wu receives $20k award from AGA, Dannon: 3 things to know
Do financial incentives promote patient adherence to CRC screening? 5 study insights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
